摘要
目的探讨经阴道超声结合CA125诊断卵巢肿瘤的价值。方法 190例卵巢肿瘤患者进行经阴道超声、彩色多普勒超声(CDFI)及CA125检测,根据检测结果进行卵巢肿瘤诊断,将诊断结果与病理学检查结果比较,观察诊断符合情况,观察卵巢良、恶性肿瘤内部血流情况和RI。结果在卵巢恶性肿瘤诊断中,阴道超声诊断符合率与血清CA125诊断及两者联合诊断比较,差异无统计学意义(P>0.05),联合诊断符合率高于血清CA125诊断,差异有统计学意义(P<0.05)。在卵巢良性肿瘤诊断中,阴道超声诊断符合率与血清CA125诊断比较,差异无统计学意义(P>0.05),联合诊断符合率高于两者单独诊断,差异有统计学意义(P<0.05)。CDFI检测卵巢良性肿瘤血流显示率为84.9%,恶性肿瘤为88.7%,两者比较差异无统计学意义(P>0.05);卵巢恶性肿瘤RI为(0.41±0.18)低于良性肿瘤的(0.67±0.18),差异有统计学意义(P<0.01)。结论阴道超声结合CA125联合诊断可提高卵巢良、恶性肿瘤的诊断准确率,从而为临床方案的确立提供依据;CDFI可作为临床诊断恶性卵巢肿瘤的重要辅助方法。
Objective To explore the value of transvaginal ultrasonograph（TVUS） and serum CA125 for the diagnosis of ovarian tumor.Methods 190 cases were given TVUS test and serum CA125 detected.Made diagnosis of ovarian tumor depending on the detected results,and compared the diagnosis with pathological examination result.Observed the diagnostic accordance situation.Observed the bloodstream in tumor and RI by CDFI.Results In the diagnosis of malignant ovarian tumor,there were no statistical differences between the diagnostic accordance rates of TVUS and CA125,as well as those of TVUS and united diagnosis（P〉0.05）,but the diagnostic accordance rate of united diagnosis was higher than that of CA125,and the difference was statistically significant（P〈0.05）.In the diagnosis of benign ovarian tumor,there was no statistical difference between the diagnostic accordance rates of TVUS and CA125（P〉0.05）,but the diagnostic accordance rate of united diagnosis was higher than that of CA125 and TVUS,and the differences were statistically significant（P〈0.05）.The display rate of bloodstream of benign ovarian tumor was 84.9%,while that of malignant ovarian tumor was 88.7%,but the difference was of no statistical significance（P〉0.05）;RI of malignant ovarian tumor was（0.41±0.18） lower than（0.67±0.18） of benign ovarian tumor,and the difference was statistically significant（P〈0.01）.Conclusion To diagnose ovarian tumor by TVUS united with serum CA125 can improve the diagnosis correct rate,and offer reference for setting up clinical treatment scheme.CDFI can be an important assistant method to diagnose malignant ovarian tumor.
出处
《临床合理用药杂志》
2010年第19期30-31,共2页
Chinese Journal of Clinical Rational Drug Use
